Lupin unveils Rivaroxaban for Oral Suspension in US following USFDA approval Ruchika Sharma2 Oct 2025 2:00 PM ISTMumbai: Global pharma major Lupin Limited has announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United...
Lupin bags USFDA approval for Rivaroxaban for Oral Suspension for thromboprophylaxis in pediatric patients Ruchika Sharma1 Oct 2025 11:37 AM ISTMumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug Administration (USFDA) for...
Shilpa Medicare gets initial authorization from EMA for Rivaroxaban Orodispersible Films Ruchika Sharma23 Sept 2025 12:30 PM ISTBengaluru: Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, has received the initial authorization from European...
Abelacimab Cuts Bleeding Risk in AF Patients Regardless of Kidney Function: AZALEA-TIMI 71 Analysis Medha Baranwal7 Sept 2025 8:45 PM ISTUSA: A secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, recently published in JAMA Cardiology, has highlighted the potential safety...
Rivaroxaban Monotherapy Effective Across Age Groups in Atrial Fibrillation Patients With Stable CAD: AFIRE Trial Medha Baranwal21 Aug 2025 9:00 AM ISTJapan: A post hoc analysis of the AFIRE randomized clinical trial has demonstrated that rivaroxaban monotherapy offers a consistent net clinical...
Venous thromboembolism in children: Rivaroxaban effective and safe even with extended use: Study Dr. Kamal Kant Kohli30 May 2025 8:45 PM ISTVenous thromboembolism (VTE) is a life-threatening complication in children with serious underlying conditions such as heart defects or cancer....
Bleeding risk with apixaban and dabigatran similar to aspirin, suggests study Dr. Kamal Kant Kohli19 Feb 2025 8:00 AM ISTA systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs)...
Abelacimab reduces ischemic Stroke Risk in Atrial Fibrillation Patients with fewer bleeding events: NEJM Dr Riya Dave31 Jan 2025 8:00 AM ISTResearchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for stroke, administration of...
Rivaroxaban Enhances Walking Distance in Peripheral Artery Disease Patients When Combined with Aspirin: NEJM Medha Baranwal3 Sept 2024 9:00 AM ISTBrazil: A recent clinical trial has shown that adding rivaroxaban to a standard aspirin regimen significantly improves walking distance for patients...
Apixaban offers safety benefits over both rivaroxaban and warfarin in patients with cirrhosis and AF: Study Dr. Kamal Kant Kohli19 July 2024 9:00 AM ISTA nationwide cohort study found that among patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiating treatment with anticoagulant...
Diltiazem use tied to serious bleeding risk in atrial fibrillation patients on apixaban or rivaroxaban: JAMA Medha Baranwal26 April 2024 9:45 AM ISTUSA: A recent study published in the Journal of the American Medical Association (JAMA) has revealed an increased risk of serious bleeding compared...
Rivaroxaban Plus Aspirin Shows Favorable Benefit-Risk Profile in PAD Patients after revascularization, suggests study Dr Riya Dave20 April 2024 8:30 AM ISTThe VOYAGER PAD trial evaluated the efficacy and safety of rivaroxaban plus aspirin compared to aspirin alone in patients with symptomatic peripheral...
